An Open-Label, Positron Emission Tomography, Phase 1 Study With [18F]MNI-792 to Determine Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 After Single-Dose Oral Administration in Healthy Subjects.

Trial Profile

An Open-Label, Positron Emission Tomography, Phase 1 Study With [18F]MNI-792 to Determine Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 After Single-Dose Oral Administration in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs TAK 935 (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 15 Feb 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 22 Sep 2015 Status changed from not yet recruiting to recruiting,as reported by ClinicalTrials.gov.
    • 16 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top